parenteral exposure, e.g. multiple transfusions (6) and intravenous drug use (7) . Hepatitis G virus was also detected in patients with no evidence of liver disease and without known risk factors, such as volunteer blood donors. Recent reports suggest that coinfection of HCV-infected patients with HGV does not influence the outcome of HCVrelated hepatitis or the response to interferon therapy (8, 9) . The aims of this study were (i) to study the prevalence of HGV infection in patients with chronic liver disease and in blood donors found positive for hepatitis B surface antigen (HBsAg) or anti-HCV; (ii) to examine whether HGV had an influence on HCV replication; and (iii) to analyze whether HGV/HCV coinfection influences the degree of liver disease.
Patients and Methods. Data and sera from 254 patients were analyzed. Of these patients, 100 had histologically proven chronic hepatitis C (Waidspital Ztirich, Switzerland), 26 had primary biliary cirrhosis, and 30 had alcoholic liver cirrhosis (University Hospital of Heraklion, Greece). Samples from 47 anti-HCV-positive and 51 HBsAg-positive blood donors were also obtained from the University Hospital of Heraklion, Greece.
Total nucleic acids were extracted from serum according to published methods (10) and subjected to reverse transcriptase reaction. For the detection of HGV sequences, two sets of primers were used. One set derives from the NS5a region (5'-CTC TTT GTG GTA GCC GAG AGA T-3', position 6904 and 5'-CGA ATG AGT CAG AGG ACG GGG TAT-3' position 7059) and gives rise to a 156bp polymerase chain reaction (PCR) fragment, and the other derives from the 5'-non coding region (5'-NCR) (5'-CGG CCA AAA GGT GGT GGA TG-3' position 100, and 5'-CGA CGA GCC TGA CGT CGG G-3' position 285) and gives rise to a 186bp PCR fragment. An Expand PCR system (Boehringer, Mannheim, Germany) was used, with 45 cycles of 1 min at 94~ 1 rain and 25 sec at 55~ and 1 rain at 72~ To confirm the specificity of amplified products, and EIA PCR employing an EIA PCR labelling and detection system was used (Boehringer Mannheim). The specific probes for the hybridization were biotinylated at the 5'-end. The probe for the NS5a region was 5'-biotin-GTT ACT GAG AGC AGC TCA GAT-3' position NS5a 152-172 and for the 5'-NCR region 5'-biotin-GGT AGC CACTAT AGG TGG G-3'.As positive control HGV, ribonucleic acid (RNA) transcripts were used, a generous gift from Genelabs Technologies, USA. Values higher than the cutoff level (3 times the mean value of 3 negative controls) in the EIA PCR assay were defined as positive.
The HCV viral load was measured using the Ampticor system (Roche, Switzerland). Antibodies against HCV and HBsAg were detected by immunoassays. Histological examination was performed using standard criteria, with fibrosis assessed semiquantitatively (11) . The Innolipa strip assay (Innogenetics, Belgium) was used for detection of HCV and analysis of genotype. For the statistical analysis, the Yates corrected chi-square method and the Wilcoxon test were applied.
Results and Discussion~
Of 100 patients with histologically proven chronic hepatitis C, 34 had used intravenous drugs, 12 had a history of transfusions, and the remaining 54 had no known risk factors (Table 1 ). Altogether, 18 of 100 (18%) HCV-infected patients were coinfected with HGV. The highest prevalence was found in intravenous drug users (32%). Patients infected with HCV alone were older (p = 0.05). Thirty-three percent of coinfected patients but only 15% of patients with HCV infection alone had HCV genotype 3a, whereas 28% of coinfected and 35% of patients infected with HCV alone had genotype lb. Genotype la was found in an equal proportion of both groups (11%). Other genotypes, including infections with a mixture of genotypes, were found in 28% of coinfected patients and in 39% of patients with HCV infection alone. Ninety-four of the 100 patients had elevated ALT levels. Although HGV/HCV coinfected patients had slightly higher ALT levels, the difference was not significant (p = 0.09,Wilcoxon test, Figure 1B) . In both groups ALT and virus load values were distributed over a broad range. Of the 18 patients coinfected with HGV and HCV, 16 (90 %) had histologically proven mild liver fibrosis; only two patients showed a severe fibrosis. Both patients with severe liver fibrosis and HGV/HCV coinfection had a mixture of HCV genotypes. All six patients with genotype 3a, all five with genotype lb, and both with genotype la had mild fibrosis. Forty-seven of 82 (58 %) patients with HCV infection alone had mild fibrosis, and 35 (42%) had severe fibrosis. The difference regarding fibrosis in HGV/HCV versus HCV-infected patients was statistically significant (p = 0.02, Yates corrected chi-square test).
Twenty-six patients with primary biliary cirrhosis (median age 63 years, range 36-78 years) were analyzed. Only four individuals had elevated ALT levels. Histologically, eight patients had grade IV liver disease, four had grade III, seven grade II, and the remaining four grade I. Three of the 26 patients were infected with HGV (11.5 %). However, ALT was elevated in only one HGV-infected patient without severe disease. Thirty patients with alcoholic liver disease were examined, two of whom had elevated ALT levels but were infected with HCV. Hepatitis G virus was detected in four patients (13 %), all of whom had normal ALT levels. The histological degree of liver injury was not different in HGV positive or negative patients. Figure 1A shows the alanine aminotransferase levels and 1B the viral load values. The mean value is indicated by a horizontal line. Alanine aminotransferase is given in U/I and the viral load in equivalent viral copies per milliliter.
HBsAg-positive blood donors and two of the anti-HCV-positive donors had elevated ALT levels. Only one of 51 (2%) HBsAg-positive blood donors was HGV positive, with a normal ALT level. In the group of anti-HCV-positive donors, five were HGV positive (10%), all of whom had normal ALT levels.
In this study we found that (i) HGV is prevalent in patients with chronic hepatitis C and different risk factors as well as in patients with other liver diseases; (ii) viremia did not differ significantly in HGV/HCV-coinfected versus HCV-infected patients; and (iii) HGV/HCV coinfection was significantly associated with mild fibrosis.
The prevalence of HGV is higher in HCV-infected patients with risk factors, such as intravenous drug use and transfusions (7, 12) . Interestingly, patients infected with HGV were younger than patients infected with HCV alone. Possibly, hepatitis G, in contrast to hepatitis C, is a self-limited viral infection that is cleared from the serum after a number of years, resulting in infection by HCV alone after years or decades. ~[lais hypothesis is supported by our previous finding that drug users who started intravenous heroin use before 1980 had a lower prevalence of HGV than those who started after 1980 (7) . Alternatively, this observation may be explained by the notion that HGV was introduced only recently in these populations. Hepatitis G virus and HCV share the paren-teral mode of transmission, but the high prevalence found in patients with alcoholic liver cirrhosis, patients with primary biliary cirrhosis, and other low-risk groups investigated in our study suggests that other modes of transmission probably occur.
Virus load and ALT levels were slightly but not significantly different in HCV-infected versus HGV/HCV-coinfected patients. Possibly, as both viruses belong to the Flaviviridae family and have a high degree of sequence homology, interferences may occur at many stages, e.g., at the replication level or during the production of viral proteins. In this study we found that HGV/HCV coinfection may lead to a rather mild course of liver disease. Similarly, Tanaka et al. (8) observed a tendency for less severe liver fibrosis in HGV/HCV-coinfected patients. Our observation, that all patients with HCV genotypes 3a and lb coinfected with HGV had only mild fibrosis, indicates that this difference is probably not due to genotypes, since lb is usually correlated with severe disease (13) .
One limitation of this study may be that the two groups of patients with chronic hepatitis, the one coinfected with HGV/HCV and the other with HCV alone, were different regarding age, mode of acquisition, and possibly other factors. This may have influenced our results regarding severity of fibrosis. In particular, the older age in the group of patients with HCV infection alone may have negatively influenced the degree of liver fibrosis.
Neither ALT levels nor the severity of liver pathology was influenced in alcoholic liver disease or primary biliary cirrhosis, suggesting that HGV infection plays rather a secondary role in the development of these diseases, with no etiologic link. The higher prevalence of HGV infection among these patients as compared to the normal population may indicate that a liver with pathology enables the persistence of HGV infection.
In conclusion, the data presented in this study support the hypothesis that HGV infection does not worsen the outcome of HCV infection and may even have a favorable effect.
